Singapore, June 15, 2024 – ChemT Biotechnology was recently featured in the NUS Alumni Magazine for its pioneering work in applying artificial intelligence to biologics manufacturing.

Singapore, April 15, 2025 – ChemT Biotechnology took part in the Bio Innovation Leaders Summit (BILS) held in Singapore this week. Co-founder Dr. Ling Wu delivered a keynote address on leveraging artificial intelligence to enhance efficiency in biologics manufacturing.

Singapore, December 15, 2024 – ChemT Biotechnology is delighted to welcome Prof. Charlie Cooney, Robert T. Haslam Professor Emeritus of Chemical Engineering at MIT, as an advisor to the company.

Singapore, December 20, 2024 – ChemT Biotechnology is working closely with Cytiva, a global leader in bioprocessing and cell therapy technologies, to support innovation and progress in cell therapy manufacturing. The collaboration focuses on integrating ChemT Bio’s flagship product, Chemplify™, into key stages of T cell production.

Singapore, August 2025 – ChemT Biotechnology Co-Founders Dr. Ling Wu and Ms. Jie Sun will speak at the ISPE (International Society for Pharmaceutical Engineering) Singapore Conference 2025, held 27–29 August at Suntec Singapore.

Singapore, August 2025 – ChemT Biotechnology has been selected for the Ignition AI Accelerator Program, an initiative backed by Tribe, NVIDIA, and Digital Industry Singapore (DISG) to advance high-impact AI innovations.

Singapore, July 2025 – ChemT Biotechnology has introduced new packaging for its first commercial product, marking a milestone in the company’s journey from R&D to market delivery. The updated design reflects ChemT’s commitment to quality, innovation, and customer experience.

Singapore, June 2025 – ChemT Biotechnology has been selected for the BioTools Innovator 2025 Accelerator Program, one of the world’s leading accelerators for the biotech sector. This year’s program saw over 420 applicants from around the globe, with only 30 companies chosen — making ChemT the first Singapore-based company in the program’s history.

New Orleans, May 2025 – ChemT Biotechnology President and Cofounder Dr. Ling Wu participated in the International Society for Cell & Gene Therapy (ISCT) 2025 conference in New Orleans, engaging with global leaders in cell therapy and highlighting its proprietary AI-designed small molecule, Chemplify, that directly addresses T-cell senescence, a universal bottleneck in cell therapy manufacturing.

Singapore April 2025 – ChemT Biotechnology Co-Founders Ms. Jie Sun and Dr. Ling Wu joined industry leaders John Ng of Dark Horse Consulting, Sen (Sean) Lin of ChemLex, and Dr. Qiusong Tang of Roche in an April 2025 panel on the future of artificial intelligence in drug discovery and biologics manufacturing.